author-photo

Debarshi Dey

MorphoSys

3

Papers

1

Citations

Citation Trend

Filter By

Papers (3) Sort By

Journal Conference Others

RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) with a Real-world Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-cell Lymphoma.

2021 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (1)
ESTIMATION OF LONG‐TERM SURVIVAL WITH TAFASITAMAB + LENALIDOMIDE (LEN) IN RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (R/R DLBCL)

2021 Hematological Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Estimation of Long-Term Survival with Tafasitamab + Lenalidomide in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

2020 Blood
Show All
- Source
- Cite
- Save
Citations (0)